CSIMarket
 


Veru Inc   (VERU)
Other Ticker:  
 

Veru Inc 's Working Capital Ratio

VERU's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Working Capital Ratio deteriorated to 1.16 below Veru Inc 's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Working Capital Ratio than Veru Inc in forth quarter 2023. While Working Capital Ratio total ranking in the forth quarter 2023 has deteriorated compared to the prior quarter from 2494 to 3095.

Explain Working Capital Ratio
How much in Current Assets VERU´s has?
What is the value of VERU´s Current Liabilities?


VERU Working Capital Ratio (Sep 30 2023)
IV. Quarter
(Jun 30 2023)
III. Quarter
(Mar 31 2023)
II. Quarter
(Dec 31 2022)
I. Quarter
(Sep 30 2022)
IV. Quarter
Y / Y Current Liabilities Change -51.06 % -0.44 % 85.35 % 187.51 % 162.81 %
Y / Y Current Assets Change -77.56 % -72.98 % -69.18 % -49.89 % -30.96 %
Working Capital Ratio MRQ 1.16 1.25 1.1 1.82 2.53
VERU's Total Ranking # 3095 # 2494 # 2816 # 445 # 2011
Seq. Current Liabilities Change -26.76 % -29.48 % -2.05 % -3.28 % 49.01 %
Seq. Current Assets Change -32.23 % -19.88 % -40.71 % -30.31 % -18.38 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 421
Healthcare Sector # 864
Overall Market # 3095


Working Capital Ratio Statistics
High Average Low
10.45 3.48 0.89
(Dec 31 2021)   (Sep 30 2018)




Financial Statements
Veru Inc 's Current Liabilities $ 20 Millions Visit VERU's Balance sheet
Veru Inc 's Current Assets $ 24 Millions Visit VERU's Balance sheet
Source of VERU's Sales Visit VERU's Sales by Geography


Cumulative Veru Inc 's Working Capital Ratio

VERU's Working Capital Ratio for the trailling 12 Months

VERU Working Capital Ratio

(Sep 30 2023)
IV. Quarter
(Jun 30 2023)
III. Quarter
(Mar 31 2023)
II. Quarter
(Dec 31 2022)
I. Quarter
(Sep 30 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -51.06 % -0.44 % 85.35 % 187.51 % 162.81 %
Y / Y Current Assets TTM Growth -77.56 % -72.98 % -69.18 % -49.89 % -30.96 %
Working Capital Ratio TTM 1.37 1.72 2.35 3.42 4.98
Total Ranking TTM # 2470 # 2168 # 1739 # 1389 # 990
Seq. Current Liabilities TTM Growth -26.76 % -29.48 % -2.05 % -3.28 % 49.01 %
Seq. Current Assets TTM Growth -32.23 % -19.88 % -40.71 % -30.31 % -18.38 %


On the trailing twelve months basis In spite of the year on year decrease in VERU's Current Liabilities to $20.28 millions, cumulative Working Capital Ratio to 1.37 below the VERU average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 499 other companies have achieved higher Working Capital Ratio than Veru Inc . While Working Capital Ratio overall ranking has improved so far to 3867, from total ranking during the twelve months ending third quarter 2023 at 4091.

Explain Working Capital Ratio
How much in Current Assets VERU´s has?
What is the value of VERU´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 500
Healthcare Sector # 1040
Within the Market # 3095


trailing twelve months Working Capital Ratio Statistics
High Average Low
9.24 3.46 1.13
(Dec 31 2021)   (Mar 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Gain Therapeutics inc  3.17 $ 13.242  Millions$ 4.179  Millions
Beigene ltd   3.16 $ 4,053.542  Millions$ 1,283.297  Millions
Alnylam Pharmaceuticals Inc   3.14 $ 2,985.452  Millions$ 949.785  Millions
Endo International Plc  3.11 $ 1,753.276  Millions$ 564.632  Millions
Aptevo Therapeutics Inc   3.09 $ 21.126  Millions$ 6.836  Millions
Morphosys Ag  3.08 $ 911.704  Millions$ 296.027  Millions
Bellicum Pharmaceuticals Inc   3.04 $ 6.848  Millions$ 2.249  Millions
Clene Inc   3.04 $ 46.446  Millions$ 15.268  Millions
Prophase Labs Inc   3.04 $ 49.794  Millions$ 16.406  Millions
Prestige Consumer Healthcare Inc   2.99 $ 388.198  Millions$ 129.704  Millions
Genprex Inc   2.96 $ 12.857  Millions$ 4.338  Millions
23andme Holding Co  2.93 $ 297.995  Millions$ 101.601  Millions
Alkermes Plc   2.91 $ 1,464.781  Millions$ 503.107  Millions
Igc Pharma Inc   2.90 $ 6.117  Millions$ 2.106  Millions
Catalyst Biosciences Inc   2.88 $ 5.132  Millions$ 1.783  Millions
Neubase Therapeutics inc   2.87 $ 13.352  Millions$ 4.650  Millions
Integrated Biopharma Inc  2.87 $ 17.759  Millions$ 6.197  Millions
Precigen Inc   2.83 $ 92.988  Millions$ 32.875  Millions
Onconova Therapeutics inc   2.79 $ 27.011  Millions$ 9.674  Millions
Organogenesis Holdings Inc   2.77 $ 225.573  Millions$ 81.482  Millions
Alaunos Therapeutics Inc   2.75 $ 12.869  Millions$ 4.676  Millions
Amicus Therapeutics inc   2.73 $ 463.256  Millions$ 169.454  Millions
Alimera Sciences Inc   2.73 $ 48.402  Millions$ 17.721  Millions
Hutchmed china Limited  2.72 $ 1,096.839  Millions$ 403.027  Millions
Insmed Inc  2.72 $ 926.576  Millions$ 341.213  Millions
Vyne Therapeutics Inc   2.72 $ 17.511  Millions$ 6.449  Millions
Seres Therapeutics Inc   2.71 $ 214.394  Millions$ 79.225  Millions
Universe Pharmaceuticals Inc  2.68 $ 36.810  Millions$ 13.754  Millions
Revelation Biosciences Inc   2.62 $ 14.147  Millions$ 5.400  Millions
Clever Leaves Holdings Inc   2.62 $ 17.934  Millions$ 6.847  Millions

Date modified: 2023-12-09T14:27:50+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com